Real-World Treatment Patterns and Clinical Outcomes in Radioiodine-Refractory Differentiated Thyroid Cancer (RAI-R-DTC) Patients Treated with Lenvatinib Monotherapy

Dr Worden reviews and discusses real-world data of lenvatinib monotherapy in patients with radioiodine-refractory differentiated thyroid cancer.

Related Videos
View All
Related Content